Center-Authored Papers

Filters: Author is Zelenetz, Andrew D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS et al..  2014.  Non-Hodgkin's Lymphomas, Version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(6):916-46. Abstract
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L et al..  2012.  Non-Hodgkin's Lymphomas, version 3.2012.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(12):1487-98. Abstract
Zelenetz AD, Becker PS.  2016.  The Role of Biosimilars.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(5 Suppl):626-9. Abstract
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP et al..  2010.  NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(3):288-334.
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2014.  Non-Hodgkin's lymphomas, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(9):1282-303. Abstract
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE et al..  2013.  Non-Hodgkin's lymphomas, version 1.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(3):257-72;quiz273. Abstract
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ et al..  2011.  Non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(5):484-560.
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2015.  Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(3):326-62. Abstract
Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH et al..  2011.  NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.. Journal of the National Comprehensive Cancer Network : JNCCN. 9 Suppl 4:S1-22. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE, Fisher RI et al..  2016.  Diffuse Large B-Cell Lymphoma Version 1.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(2):196-231. Abstract
W
Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, McLaughlin P, Press OW, Zelenetz AD.  2011.  Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.. Leukemia & lymphoma. 52(7):1188-99. Abstract
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Caimi P, Fayad LE et al..  2017.  NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(3):293-311. Abstract
T
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
S
Sehn LH, Goy A, Offner FC, Martinelli G, Caballero DM, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE et al..  2015.  Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(30):3467-3474. Abstract
P
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
L
Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M et al..  2015.  Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.. Cancer. Abstract
H
Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirani R, Evens AM et al..  2014.  A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.. British journal of haematology. 165(3):358-63. Abstract
Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE et al..  2016.  NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(9):1067-79. Abstract
F
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I et al..  2014.  Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.. The New England journal of medicine. Abstract
C
Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH et al..  2015.  Management of adverse events associated with idelalisib treatment: expert panel opinion.. Leukemia & lymphoma. :1-8. Abstract
B
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
A
Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE et al..  2015.  Acute Lymphoblastic Leukemia, Version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(10):1240-79. Abstract